Abstract:Background: Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), a novel betacoronavirus, has caused an outburst of pneumonia cases in Wuhan, China. We report the production of specific IgM and IgG antibodies after the infection of SARS-CoV-2 and its implication for the diagnosis, pathology and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. Methods: Test results for SARS-CoV-2 IgM and IgG antibodies of 221 confirmed COVID-19 patients were retrospectively examined, and their clinical data were collected and analyzed based on various subgroups. SARS-CoV-2 IgM and IgG antibodies were determined with the chemiluminescence method. Findings: The concentration (S/CO) of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, with a median of 17.38 (IQR 4.39-36.4) for IgM and 5.59 (IQR 0.73-13.65) for IgG. Detection rates reached highest on day 16-18 and day 19-21 for IgM and IgG, which were 73.6% and 98.6%, respectively, with significantly higher concentration of IgG in critically ill patients than in those with mild to moderate disease (P=0.027). The concentration of the antibodies on day 16-21 is not correlated with the course or outcome of the disease (Spearman r < 0.20, P > 0.05). Nasopharyngeal swabs revealed positive SARS-CoV-2 RNA in up to 52.7% of recovered patients after discharge, whose IgG proved to be significantly lower than that of those with negative RNA results (P = 0.009). IgG and IgM were tested twice within 14 days after discharge with a 7-day interval, and the second testing of these antibodies displayed a decrease in concentration of 21.2% (IQR, 11.2%34.48%) for IgG and 23.05% (IQR, -27.96%46.13%) for IgM, without statistical significance between the patients with re-detectable positive RNA results and those with negative RNA results after discharge. However, those with positive results experienced a count decrease in lymphocyte subsets. Interpretation: The concentration of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, and antibody testing on day 16-21 is associated with increased detection rates, but the antibody concentration does not affect the course and outcome of the infection. Recovering patients with re-detectable positive SARS-CoV-2 RNA displayed lower concentration of IgG, but the downward trend of IgG during recovery indicated its limited duration of protection, and the protective effect of IgG remains to be investigated.

Dynamic Changes in IgG and IgM Antibodies As Clinical Indicators During Recovery Stage in Patients with Severe Acute Respiratory Syndrome

Dynamic Changes of Viral Load and Antibodies Level in the Patients of Severe Acute Respiratory Syndrome

[A Follow Up Study of Total IgM, IgG, Nucleoprotein and Spike Protein Antibodies Against Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS].

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

The Dynamic Changes of Antibodies Against SARS-CoV-2 During the Infection and Recovery of COVID-19

[Prospective Clinical Study on Serum Immunity in IgG-antibodies Positive Patients Convalescent from Severe Acute Respiratory Syndrome].

The Dynamic Changes of Serum IgM and IgG Against SARS‐CoV‐2 in Patients with COVID‐19

The Follow-up Study on the Health Status of Convalescent Patients Recovered from SARS in Tianjin

[Prospective 2-Year Clinical Study of Patients with Positive IgG-antibodies after Recovering from Severe Acute Respiratory Syndrome].

Longitudinal Profile of Antibodies Against Sars-Coronavirus in Sars Patients and Their Clinical Significance

Dynamic Changes in Anti-Sars-cov-2 Antibodies During SARS-CoV-2 Infection and Recovery from COVID-19

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.

Evaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay

Comparison of Immunoglobulin G Responses to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS.

[Primary Investigation on the Changing Mode of Plasma Specific IgG Antibody in SARS Patients and Their Physicians and Nurses].

Characterization of antibody responses to SARS‐CoV‐2 in convalescent COVID‐19 patients

Study on the Response of Specific Antibodies Against SARS-CoV in Patients Infected with SARS

Dynamic Observation to SARS-CoV Antibody and Antigen in Late 2003 in Guangdong

The Production and Clinical Implications of SARS-CoV-2 Antibodies

Serology of Severe Acute Respiratory Syndrome: Implications for Surveillance and Outcome

Dynamic Changes of IgM and IgG Antibodies in Asymptomatic Patients As an Effective Way to Detect SARS‐CoV‐2 Infection